Immunomodulators Market to Surpass US$ 156378.2 Million by 2028

The Global Immunomodulators Market, by Product Type (Immunosuppressants (Calcineurin Inhibitors, Glucocorticoids, Antimetabolites, and Others), Immunostimulants (Vaccines, Antibodies, and Others)), by Application (Oncology, Respiratory, HIV, and Others), by End User (Hospitals, Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America), is estimated to be valued at US$ 91850.0 Million in 2021 and is projected to exhibit a CAGR of 7.9% during the forecast period (2021-2028).

The increasing launch of immunomodulating drugs is expected to favor the immunomodulators market growth during the forecast period. For instance, in January 2020, Bristol Myers Squibb Company, an American multinational pharmaceutical company, launched Zeposia, a new medication, used for the treatment of multiple sclerosis. It can help with both the physical and cognitive elements of multiple sclerosis.

Global Immunomodulators Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 pandemic has affected immunomodulators market globally. The players operating in the immunomodulators market are facing major challenges on various fronts due to the COVID-19 pandemic. COVID-19 disease has affected the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Although for majority of market players the COVID-19 outbreak had a minimal impact on sales generated by immunological drugs; owing to an improved supply chain management, enhanced R&D capability, and an increased investment in manufacturing management & quality control. For instance, Roche's global supply network of medications and diagnostics remains intact, according to its quarterly reports for 2020, and pharmaceutical division sales climbed by 7% compared to 2019. In addition, the Himalaya Drug Company announced the results of a clinical research in December 2020, stating that herbal Global Immunomodulators are useful as an adjuvant treatment for COVID-19 patients.

Browse 35 Market Data Tables and 30 Figures spread through 179 Pages and in-depth TOC on “Global Immunomodulators Market, by Product Type (Immunosuppressants (Calcineurin Inhibitors, Glucocorticoids, Antimetabolites, and Others), Immunostimulants (Vaccines, Antibodies, and Others)), by Application (Oncology, Respiratory, HIV, and Others), by End User (Hospitals, Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)- Forecast to 2028” 

To know the latest trends and insights prevalent in the Immunomodulators Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/immunomodulators-market-4609

Increasing acquisitions and collaboration among key players is expected to propel the growth of the global immunomodulators market over the forecast period. For instance, in March 2021, Horizon Therapeutics plc. which is focused on the discovery, development, and commercialization of medicines for treatment of rare, autoimmune, and severe inflammatory diseases, announced that it has completed the acquisition of Viela Bio, Inc. a clinical-stage biotechnology company. This acquisition will expand the company’s medicine portfolio.

Key Takeaways of the Global Immunomodulators Market:

• The global immunomodulators market is expected to exhibit a CAGR of 7.9% during the forecast period, owing to the high prevalence of chronic diseases and more product approval by regulatory authorities for their treatment. For instance, in January 2021, Aurinia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive medication regimen to treat adult patients with active lupus nephritis.
• Among product type, the immunosuppressants segment accounted for the majority of the global immunomodulators market share in 2019 and is expected to grow in the forecast period. The use of these medications to treat autoimmune illnesses including lupus and alopecia areata is responsible for this increase. Furthermore, the availability of a diverse variety of these pharmaceuticals capable of efficiently treating the ailments listed above will promote the segment's growth.
• Major players operating in the global immunomodulators market include F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.